Golden Biotechnology Corporation
Golden Biotechnology Corporation engages in research and development of new drug in Taiwan. The company offers Antroquinonol for the treatment of pancreatic cancer, acute myeloid leukemia, blood diseases, non-small cell lung cancer, COVID-19, and other diseases. It is also involved in development and sale of health foods and supplements, as well as provides products for oncology, infectious, and … Read more
Golden Biotechnology Corporation (4132) - Total Liabilities
Latest total liabilities as of June 2024: NT$337.23 Million TWD
Based on the latest financial reports, Golden Biotechnology Corporation (4132) has total liabilities worth NT$337.23 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Golden Biotechnology Corporation - Total Liabilities Trend (2019–2023)
This chart illustrates how Golden Biotechnology Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Golden Biotechnology Corporation Competitors by Total Liabilities
The table below lists competitors of Golden Biotechnology Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Laboratorio Reig Jofre S.A
MC:RJF
|
Spain | €138.18 Million |
|
Tofu Restaurant Co Ltd
TWO:2752
|
Taiwan | NT$963.63 Million |
|
Besiktas Futbol Yatirimlari Sanayi ve Ticaret AS
IS:BJKAS
|
Turkey | TL19.05 Billion |
|
KIRAC GALVANIZ
IS:TCKRC
|
Turkey | TL1.84 Billion |
|
Two Rivers Financial Group Inc
PINK:TRVR
|
USA | $1.08 Billion |
|
GCT Semiconductor Holding Inc
NYSE:GCTS
|
USA | $104.42 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down Golden Biotechnology Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Golden Biotechnology Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Golden Biotechnology Corporation (2019–2023)
The table below shows the annual total liabilities of Golden Biotechnology Corporation from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$312.11 Million | -7.85% |
| 2022-12-31 | NT$338.70 Million | -25.02% |
| 2021-12-31 | NT$451.72 Million | +48.47% |
| 2020-12-31 | NT$304.26 Million | +3.16% |
| 2019-12-31 | NT$294.95 Million | -- |